Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.50 |
| ▸ | CDK4 | P11802 | 10/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 3/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597472 | 0.82 | CDK2 (0.49) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL4613610 | 0.80 | CDK2 (0.58) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL6600528 | 0.78 | CDK2 (0.50) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL4615032 | 0.77 | CDK2 (0.77) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL2084979 | 0.73 | CDK2 (0.65) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL1412198 | 0.72 | CDK2 (0.50) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL5204200 | 0.71 | CDK2 (0.59) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL12275151 | 0.70 | BRD4 (0.54) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL6597467 | 0.70 | CDK2 (0.73) | CDK2CDK4AURKBCCNE1AURKA | |
| SCHEMBL7467187 | 0.69 | CDK2 (0.60) | CDK2CDK4AURKBCCNE1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100425239-C | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LTD (GB) | 2008-10-15 | — | — | CN | claimed |
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | claimed |
| CN-1720049-A | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LTD (GB) | 2006-01-11 | — | — | CN | claimed |
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LIMITED (GB) | 2005-12-22 | — | — | US | claimed |
| EP-1572211-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | Cyclacel Limited (GB) | 2005-09-14 | — | — | EP | claimed |
| WO-2004056368-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| CN-100425239-C | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LTD (GB) | 2008-10-15 | — | — | CN | disclosed |
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| CN-1720049-A | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LTD (GB) | 2006-01-11 | — | — | CN | disclosed |
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LIMITED (GB) | 2005-12-22 | — | — | US | disclosed |
| EP-1572211-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | Cyclacel Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056368-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056368-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | HRH2, HRH3, CYTH3 | CDK2 810/4885CDK4 1254/4885AURKB 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.